Moderna announced successful Phase 1 clinical trial results this week for this flu-fighting mRNA-1440. The vaccine is intended to combat Influenza Virus H10N8, a strain of bird flu which began commonly appearing in 2014. In this double blind study, Moderna reported that only three trial participants (of thirty-one) showed adverse side effects which were moderate and reversible. The company noted that this trial is showing positive outcomes in the use of mRNA vaccine technology which stimulates cell production and expression of viral antigenic proteins. Read the full press release here.